Andrew Parker
Arisgen SA, Switzerland
Posters-Accepted Abstracts: J Diabetes Metab
Arisgen has developed a novel lipid based formulation technology that can concomitantly promote permeation and overcome poor peptide oral bioavailability. This technology is called ArisCrown and is based on the selective and reversible masking of peptide functional groups by novel and proprietary biodegradable cyclic (BCC) compounds. The BCC/peptide complex is combined with a range of known GRAS lipidic components and the final formulation optimized to maintain peptide stability, solubility and conformation. Our first clinical application of the technology will be a formulation of exenatide that can be delivered as a sub-lingual fast-melt tablet to replace the need for daily injections. We have demonstrated in mice that sub-lingual administration of ArisCrown Exenatide (ARG011) is able to control glycaemia, as determined by glucose and insulin regulation, as well as food intake, in a manner equivalent to i.p. injection of unformulated peptide. In addition in monkey studies we have demonstrated that ARG011 combined in a buccal patch is able to deliver the peptide and control PD markers of glycaemia equivalent to s.c. injected peptide. We are concluding our pre-clinical assessment of the technology. Data on pre-clinical safety and tolerability will be presented as well as our immediate clinical plans.
Email: andrew.parker@arisgen.com
